每(mei)經AI快訊，畢得(de)醫藥(yao)1月(yue)27日晚間公(gong)(gong)告，公(gong)(gong)司(si)擬(ni)向維梧蘇州、Vivo Cypress發(fa)(fa)行股(gu)(gu)份購買(mai)維播投(tou)資的(de)部分(fen)股(gu)(gu)權(quan)，以取(qu)得(de)維播投(tou)資控制權(quan)，從(cong)而實現對最(zui)終(zhong)(zhong)目標(biao)公(gong)(gong)司(si)Combi的(de)控制，并向不(bu)超過35名特定(ding)投(tou)資者發(fa)(fa)行股(gu)(gu)份募集配套資金。維播投(tou)資系(xi)持股(gu)(gu)型公(gong)(gong)司(si)，此(ci)次交易的(de)具體交易價格尚未確定(ding)。公(gong)(gong)司(si)與最(zui)終(zhong)(zhong)目標(biao)公(gong)(gong)司(si)Combi同屬藥(yao)物分(fen)子(zi)砌塊(kuai)和科學(xue)試劑研發(fa)(fa)、生產(chan)和銷售企業。此(ci)次交易后，公(gong)(gong)司(si)可將(jiang)Combi公(gong)(gong)司(si)的(de)產(chan)品(pin)線納入業務(wu)體系(xi)，進(jin)一步擴充藥(yao)物分(fen)子(zi)砌塊(kuai)和科學(xue)試劑的(de)產(chan)品(pin)種(zhong)類(lei)，強化公(gong)(gong)司(si)市場競爭力(li)。公(gong)(gong)司(si)股(gu)(gu)票將(jiang)于2月(yue)5日復牌。